Tyrosine Kinase Inhibition: A complete shut down of the neovascularization pathway is the goal

David M. Brown

Tyrosine Kinase Inhibition: A complete shut down of the neovascularization pathway is the goal

Research output: Contribution to journal › Article › peer-review

Abstract

Targeting the "fuel injector" of neovascularization (tyrosine kinase) appears to make sense. There is some initial anatomic validation to tyrosine kinase inhibition, but the devil lies in the details. Whether this route is the answer that will help change the way we treat retinal disease in the future is yet to be determined.

Original language	English (US)
Pages (from-to)	3-4
Number of pages	2
Journal	Retina Today
Issue number	AUGUST-SUPPL.
State	Published - Jul 1 2010

ASJC Scopus subject areas

Ophthalmology

Cite this

@article{a07cbc9ac5084e77ab8dcab6d84bb74a,

title = "Tyrosine Kinase Inhibition: A complete shut down of the neovascularization pathway is the goal",

abstract = "Targeting the {"}fuel injector{"} of neovascularization (tyrosine kinase) appears to make sense. There is some initial anatomic validation to tyrosine kinase inhibition, but the devil lies in the details. Whether this route is the answer that will help change the way we treat retinal disease in the future is yet to be determined.",

author = "Brown, {David M.}",

year = "2010",

month = jul,

day = "1",

language = "English (US)",

pages = "3--4",

journal = "Retina Today",

issn = "1825-0572",

publisher = "Retina Today",

number = "AUGUST-SUPPL.",

}

TY - JOUR

T1 - Tyrosine Kinase Inhibition

T2 - A complete shut down of the neovascularization pathway is the goal

AU - Brown, David M.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Targeting the "fuel injector" of neovascularization (tyrosine kinase) appears to make sense. There is some initial anatomic validation to tyrosine kinase inhibition, but the devil lies in the details. Whether this route is the answer that will help change the way we treat retinal disease in the future is yet to be determined.

AB - Targeting the "fuel injector" of neovascularization (tyrosine kinase) appears to make sense. There is some initial anatomic validation to tyrosine kinase inhibition, but the devil lies in the details. Whether this route is the answer that will help change the way we treat retinal disease in the future is yet to be determined.

UR - http://www.scopus.com/inward/record.url?scp=82255180629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255180629&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:82255180629

SN - 1825-0572

SP - 3

EP - 4

JO - Retina Today

JF - Retina Today

IS - AUGUST-SUPPL.

ER -

Tyrosine Kinase Inhibition: A complete shut down of the neovascularization pathway is the goal

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this